Real-world experience with CLAIRYG® 50 mg/mL (intravenous immunoglobulin) in children under 12 years with primary immunodeficiency or immmune thrombocytopenia: a post-approval safety study

• Main Authors: Nizar Mahlaoui (Author), Fanny Fouyssac (Author), Françoise Mazingue (Author), Coralie Mallebranche (Author), Malika Barthez-Toullec (Author), Lamia Denti (Author), Kalaivani Ruhier (Author), Marie-Hélène (Author), Aude Marie-Cardine (Author), Nathalie Aladjidi (Author), Jean-Louis Stephan (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

IntroductionThis study presents the results of a real-life, multicenter, prospective, post-approval safety evaluation of Clairyg® 50 mg/mL, a 5% intravenous immunoglobulin (IVIg) liquid, in 59 children (aged < 12 years) with primary immunodeficiency diseases (PID) (n = 32) or immune thrombocytope...